WHC is still in active development. Read this to understand our approach.
depiction of PJMPHNIQZUBGLI-UHFFFAOYSA-N.svg
tripsit

fentanyl

Verificar en tripsit

psychonaut

Fentanyl

Verificar en psychonaut

isomerdesign

Fentanyl

Verificar en isomerdesign

pubchem

Fentanyl

Verificar en pubchem

druglab

Fentanyl

Verificar en druglab

drugmap

Fentanyl

Verificar en drugmap

wiki

Fentanyl

Verificar en wiki

Data

InChI: InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3

Sinónimos: Durogesic,Durotep MT,Fentanyl-100,Fentora,Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-, 437-38-7,N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide,N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide,DB00813,Fentanyl Transdermal System, Fentanyl-50,Fentanyl CII, Subsys,437-38-7,Fentanyl 1.0 mg/ml in Methanol,FENTANYL-HCl,N-(2-Phenethyl-4-piperidyl)-N-phenyl-propanamide,Duragesic-75,FENTANYL [VANDF], Fentanyl-37,HSDB 3329,FENTANYL [INN], Fentanyl-75,IONSYS,Q407541,DSSTox_CID_3049,1-(2-Phenylethyl)-4-(N-propananilido)piperidine,Fentanila,NCGC00168252-01,Fentanila [INN-Spanish],CHEMBL596,PROPANAMIDE, N-PHENYL-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL), Fentanil,FENTANYL [HSDB],Duragesic-25,Oprea1_152073,Fentanyl solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,Fentanyl-75, Fentanil [DCIT],N-(1-Phenylethyl-4-piperidinyl)propionanilide,L001275,AD-923,FENTANYL [EMA EPAR VETERINARY],PDSP2_000846,UF599785JZ, N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide,D00320,CHEBI:119915,BDBM50008984, Matrifen,FENTANYL [EMA EPAR], Sentonil,Matrifen,Fentanyl-50, Abstral, Durogesic,Fentanil [DCIT],Subsys (TN),Tranq component fentanyl,DTXCID103049,N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide(Fentanyl),EN-3267, Duragesic-100, Fentanila [INN-Spanish],Oprea1_207148,R 4263,Duragesic,Duragesic-100,Abstral-,FENTANYL [JAN],BIDD:GT0555,CS-7211, Duragesic-25,FENTANYL CII [USP-RS],Fendrop, Fentanila,BRN 0494484, Duragesic-50,Fentanyl solution, 100 mug/mL in methanol, ampule of 1 mL, certified reference material,HY-U00158,JNS020QD,N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide,N-Phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]propanamide #, Duragesic,Fentanyl-12, N-Phenethyl-4-(N-propionylanilino)piperidine,FENTANYL [EP MONOGRAPH], Fentanyl-25,Fentanyl (JAN/USP/INN), Fentanest,Fentanyl-25, Fentanyl-100,N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide, Fentora,DSSTox_RID_76851, N-(1-Phenethyl-4-piperidyl)propionanilide,FENTANYL [WHO-DD],Fentanylum [INN-Latin],N02AB03,Duragesic (TN), Sublimase, Duragesic-12,SCHEMBL8804,1-Phenethyl-4-(N-phenylpropionamido)piperidine,Duragesic-12,N-(2-Phenethyl-4- piperidyl)propionanilide,Sentonil,DSSTox_GSID_23049,N-Phenethyl-4-(N-propionylanilino)piperidine, fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals,Fentanest,Fentanylum,Fentanyl,N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide, Sublimaze Preservative Free,Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-,AD 923,FENTANYL [USAN], Fentanyl-62,UNII-UF599785JZ, Phentanyl,Sublimaze,FENTANYL [USP MONOGRAPH],Sublimase,FENTANYL [GREEN BOOK],Durogesic d-trans,N-(1-Phenethyl-4-piperidyl)propionanilide,R4263,Fentanyl 0.1 mg/ml in Methanol,GTPL1626, IONSYS, Fentanyl Citrate Preservative Free,DTXSID9023049,N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide, Duragesic-75,1-Phenethyl-4-N-propionylanilinopiperidine, Fentanyl-87, Fentanylum,Duragesic-50,Phentanyl,PDSP1_000860, 1-Phenethyl-4-N-propionylanilinopiperidine,IDS-NF-001,Recuvyra,FENTANYL [EP IMPURITY],Subsys,FENTANYL [MI], Lazanda, Fentanylum [INN-Latin],Fentanil,7V7,CAS-437-38-7,ZINC2522669, Actiq,En3267, Fentanyl Citrate,5-22-08-00049 (Beilstein Handbook Reference),PecFent,fent, Onsolis,fentanyl,Propionanilide, N-(1-phenethyl-4-piperidyl)-,Tox21_112611,EINECS 207-113-6, Sublimaze,Fentanyl [USAN:USP:INN:BAN],FENTANYL [MART.],FENTANYL [ORANGE BOOK], Fentanyl-12,Epitope ID:153507


Estimated data

Solubilidad: -3.873 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 98.8% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.